Clarithromycin Targets Neutrophilic Airway Inflammation in Refractory Asthma
Top Cited Papers
Open Access
- 15 January 2008
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 177 (2), 148-155
- https://doi.org/10.1164/rccm.200707-1134oc
Abstract
Rationale: Patients with refractory asthma have persistent symptoms despite maximal treatment with inhaled corticosteroids and long-acting bronchodilators. The availability of add-on therapies is limited, and effective add-on therapies that target noneosinophilic airway inflammation are needed. Macrolide antibiotics, such as clarithromycin, have in vitro efficacy against IL-8 and neutrophils, key inflammatory mediators in noneosinophilic asthma. Objectives: To determine the efficacy of clarithromycin in patients with severe refractory asthma and specifically in a subgroup of patients with noneosinophilic asthma. Methods: Subjects with severe refractory asthma (n = 45) were randomized to receive clarithromycin (500 mg twice daily) or placebo for 8 weeks. Measurements and Main Results: The primary outcome for this study was sputum IL-8 concentration. Other inflammatory outcomes assessed included sputum neutrophil numbers and concentrations of neutrophil elastase and matrix metalloproteinase (MMP)-9. Clinical outcomes were also assessed, including lung function, airway hyperresponsiveness to hypertonic saline, asthma control, quality of life, and symptoms. Clarithromycin therapy significantly reduced airway concentrations of IL-8 and neutrophil numbers and improved quality-of-life scores compared with placebo. Reductions in neutrophil elastase and MMP-9 concentrations were also observed. These reductions in inflammation were most marked in those with refractory noneosinophilic asthma. Conclusions: Clarithromycin therapy can modulate IL-8 levels and neutrophil accumulation and activation in the airways of patients with refractory asthma. Macrolide therapy may be an important additional therapy that could be used to reduce noneosinophilic airway inflammation, particularly neutrophilic inflammation, in asthma. Clinical trial registered with the Australian Clinical Trials Registry www.actr.org.au (No. 12605000318684).Keywords
This publication has 39 references indexed in Scilit:
- Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthmaThorax, 2007
- Inflammatory subtypes in asthma: Assessment and identification using induced sputumRespirology, 2006
- Heterogeneity of Airway Inflammation in Persistent AsthmaSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2001
- Proceedings of the ATS Workshop on Refractory AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Development and validation of a questionnaire to measure asthma controlEuropean Respiratory Journal, 1999
- Evidence That Severe Asthma Can Be Divided Pathologically into Two Inflammatory Subtypes with Distinct Physiologic and Clinical CharacteristicsAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Epidemiological Association of Airway Inflammation with Asthma Symptoms and Airway Hyperresponsiveness in ChildhoodAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Interleukin 1β, Tumor Necrosis Factor Alpha, and Interleukin 8 in Bronchoalveolar Lavage Fluid of Patients with Diffuse Panbronchiolitis: A Potential Mechanism of Macrolide TherapyRespiration, 1996
- Measuring Quality of Life in AsthmaAmerican Review of Respiratory Disease, 1993
- Inhalation provocation tests using nonisotonic aerosolsJournal of Allergy and Clinical Immunology, 1989